Literature DB >> 28253087

Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.

Zelalem Petros1, Eyasu Makonnen1, Eleni Aklillu2.   

Abstract

Idiosyncratic drug-induced hepatotoxicity is a formidable challenge for rational drug discovery and development, as well as the science of personalized medicine. There is evidence that hereditary factors, in part, contribute to drug toxicity. This expert analysis and review offer the insights gained, and the challenges ahead, for genome-wide association studies (GWASs) of idiosyncratic drug-induced hepatotoxicity. Published articles on genome-wide and subsequent replication studies were systematically searched in the PubMed electronic database. We found that the genetic risk variants that were identified genome-wide, and replication confirmed, are mainly related to polymorphisms in the human leukocyte antigen (HLA) region that include HLA-DQB1*06:02 for amoxicillin-clavulanate, HLA-B*57:01 for flucloxacillin, HLA-DRB1*15:01 for lumiracoxib, and HLA-DRB1*07:01 for lapatinib and ximelagatran-induced hepatotoxicity. Additionally, polymorphisms in ST6 β-galactosamide α-2, 6-sialyltranferase-1 (ST6GAL1), which plays a role in systemic inflammatory response, and variants in intron of family with sequence similarity-65 member-B (FAM65B) that play roles in liver inflammation displayed association with flucloxacillin and antituberculosis drug-induced hepatotoxicity, respectively. Taken together, these GWAS findings offer molecular leads on the central role that the immune system plays in idiosyncratic drug-induced hepatotoxicity. We conclude the expert review with a brief discussion of the salient challenges ahead. These include, for example, the need for discursive discovery paradigms that incorporate alternating GWASs and candidate gene studies, as well as the study of the environtome, the entire complement of environmental factors, including science and innovation policies that enact on global society and the human host, and by extension, on susceptibility for idiosyncratic drug-induced hepatotoxicity.

Entities:  

Keywords:  GWAS; disruptive innovation; drug discovery and development; drug-induced hepatotoxicity; drug-induced liver injury; genome-wide study; translational research

Mesh:

Substances:

Year:  2017        PMID: 28253087      PMCID: PMC5346905          DOI: 10.1089/omi.2017.0006

Source DB:  PubMed          Journal:  OMICS        ISSN: 1536-2310


  89 in total

1.  Accumulation of free ADP-ribose from mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels.

Authors:  Anne-Laure Perraud; Christina L Takanishi; Betty Shen; Shin Kang; Megan K Smith; Carsten Schmitz; Heather M Knowles; Dana Ferraris; Weixing Li; Jie Zhang; Barry L Stoddard; Andrew M Scharenberg
Journal:  J Biol Chem       Date:  2004-11-23       Impact factor: 5.157

Review 2.  Genome-wide association studies for common diseases and complex traits.

Authors:  Joel N Hirschhorn; Mark J Daly
Journal:  Nat Rev Genet       Date:  2005-02       Impact factor: 53.242

3.  HLA association of amoxicillin-clavulanate--induced hepatitis.

Authors:  M L Hautekeete; Y Horsmans; C Van Waeyenberge; C Demanet; J Henrion; L Verbist; R Brenard; C Sempoux; P P Michielsen; P S Yap; J Rahier; A P Geubel
Journal:  Gastroenterology       Date:  1999-11       Impact factor: 22.682

4.  Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

Authors:  Ann K Daly; Guruprasad P Aithal; Julian B S Leathart; Richard A Swainsbury; Tarana Singh Dang; Christopher P Day
Journal:  Gastroenterology       Date:  2006-11-17       Impact factor: 22.682

5.  Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.

Authors:  Yi-Shin Huang; Wei-Juin Su; Yi-Hsiang Huang; Chih-Yen Chen; Full-Young Chang; Han-Chieh Lin; Shou-Dong Lee
Journal:  J Hepatol       Date:  2007-03-06       Impact factor: 25.083

Review 6.  Genome-wide association studies in pharmacogenomics: successes and lessons.

Authors:  Alison A Motsinger-Reif; Eric Jorgenson; Mary V Relling; Deanna L Kroetz; Richard Weinshilboum; Nancy J Cox; Dan M Roden
Journal:  Pharmacogenet Genomics       Date:  2013-08       Impact factor: 2.089

Review 7.  Mechanisms of drug-induced liver injury.

Authors:  Liyun Yuan; Neil Kaplowitz
Journal:  Clin Liver Dis       Date:  2013-08-01       Impact factor: 6.126

Review 8.  Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis.

Authors:  Guruprasad P Aithal; Jane I Grove
Journal:  Semin Liver Dis       Date:  2015-12-16       Impact factor: 6.115

9.  SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury.

Authors:  Ling-Min Li; Lei Chen; Guo-Hong Deng; Wen-Ting Tan; Yun-Jie Dan; Rong-Quan Wang; Wen-Sheng Chen
Journal:  Mol Med Rep       Date:  2012-05-03       Impact factor: 2.952

10.  Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.

Authors:  Sabina Mugusi; Eliford Ngaimisi; Mohamed Janabi; Omary Minzi; Muhammad Bakari; Klaus-Dieter Riedel; Juergen Burhenne; Lars Lindquist; Ferdinand Mugusi; Eric Sandstrom; Eleni Aklillu
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

View more
  3 in total

1.  Conference report: pharmacogenomics in special populations at WCP2018.

Authors:  Guilherme Suarez-Kurtz; Eleni Aklillu; Yoshiro Saito; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2019-01-24       Impact factor: 4.335

Review 2.  What have we learned from animal models of idiosyncratic, drug-induced liver injury?

Authors:  Robert A Roth; Patricia E Ganey
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-05-04       Impact factor: 4.481

3.  CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study.

Authors:  Wondmagegn Tamiru Tadesse; Eulambius Mathias Mlugu; Workineh Shibeshi; Wondwossen Amogne Degu; Ephrem Engidawork; Eleni Aklillu
Journal:  J Pers Med       Date:  2022-06-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.